Status:
COMPLETED
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg...
Eligibility Criteria
Inclusion
- Stage I-IIIa breast cancer
- Postmenopausal
- Recent surgery for breast cancer
Exclusion
- Metastatic disease
- Invasive bilateral disease
- Clinical or radiological evidence of existing fracture in spine or hip
- Other protocol-defined inclusion / exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
527 Patients enrolled
Trial Details
Trial ID
NCT00171314
Start Date
March 1 2004
Last Update
April 11 2012
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Buenos Aires, Argentina
2
Novartis Investigative Site
Rosario - Santa Fe, Argentina
3
Novartis Investigative Site
Aalst, Belgium
4
Novartis Investigative Site
Anderlecht, Belgium